Skip to main content
CATCongressional Accountability Tracker
OfficialsLegislationCommitteesWatch LivePulseForecastMisconductPresidentLearn
CAT

Congressional Accountability Tracker. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Forecast

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live
  • About This Site

Data Sources

Congress.gov
Bills, members, votes
GovInfo
Floor speeches, reports, bill text
Federal Election Commission
Campaign finance
VoteView
Ideology scores (DW-NOMINATE)
GovTrack
Misconduct data (CC0)
U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Congressional Accountability Tracker

Floor Speech2026-03-19

Text of Senate Amendment 4701

Peter Welch
Peter Welch
DVT · Senator
Share:

Full Text

Text of Senate Amendment 4701

Congressional Record, Volume 172 Issue 50 (Thursday, March 19, 2026) [Congressional Record Volume 172, Number 50 (Thursday, March 19, 2026)] [Senate] [Page S1406] From the Congressional Record Online through the Government Publishing Office [ www.gpo.gov ] SA 4701. Mr. WELCH (for himself, Mr. Wyden, Ms. Cortez Masto, Mr. Lujan, and Mr. Van Hollen) submitted an amendment intended to be proposed by him to the bill S. 1383, to establish the Veterans Advisory Committee on Equal Access, and for other purposes; which was ordered to lie on the table; as follows: At the appropriate place, insert the following: SEC. __. TREATMENT OF ORPHAN DRUGS UNDER THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM. (a) In General.--Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) is amended-- (1) in paragraph (1), in the matter preceding subparagraph (A), by striking ``through (4)'' and inserting ``and (3)''; (2) in paragraph (3)-- (A) by striking subparagraph (A); (B) by redesignating subparagraphs (B) and (C) as subparagraphs (A) and (B), respectively; and (C) in subparagraph (A)(iii), as redesignated by subparagraph (B) of this paragraph, by striking ``with respect to'' and inserting ``subject to paragraph (4), with respect to''; and (3) by striking paragraph (4) and inserting the following new paragraph: ``(4) Treatment of orphan drugs.--In the case of a drug that is designated as a drug for one or more rare diseases or conditions and for which the only approved indication (or indications) is for one or more such rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act), paragraph (3)(A) shall be applied by substituting `$400,000,000' for `$200,000,000' in clause (i) of such paragraph.''. (b) Application.--The amendments made by subsection (a) shall apply with respect to initial price applicability years (as defined in section 1191(b) of the Social Security Act (42 U.S.C. 1320f(b))) beginning on or after January 1, 2028. ______
View original source →